Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim has entered into an exclusive worldwide collaboration and license agreement with OSE Immunotherapeutics for the development of a new checkpoint inhibitor to treat solid tumors.
Subscribe to our email newsletter
Under the deal, the companies will jointly develop OSE-172, which is a SIRP-alpha antagonist targeting myeloid lineage cells.
SIRP-alpha is a receptor showed by myeloid lineage cells such as dendritic Cells (DCs), tumor-associated macrophages (TAMs) and myeloid-derived suppressor Cells (MDSCs).
OSE-172 is said to avoid the ligand CD47 from binding and activating the cellular inhibitory effects of SIRP-alpha.
The deal has provided Boehringer with global rights to develop, register and commercialize OSE-172.
As per terms of the deal, OSE Immunotherapeutics will secure a €15m upfront payment from Boehringer.
OSE is also eligible to receive additional short-term milestones of up to €15m after initiating phase 1 clinical study.
In addition, OSE is eligible to secure more than €1.1bn based on the achievement of pre-specified development, commercialization and sales milestones, and royalties on worldwide net sales.
OSE Immunotherapeutics CEO Dr Dominique Costantini said: “This partnership with Boehringer Ingelheim is a real recognition of the value of our innovative approach to treating cancer and will create an exciting new alliance to fuel the phase 1 development of OSE-172.”
Boehringer Ingelheim cancer immunology and immune modulation research global head Dr Jonathon Sedgwick said: “A key area of focus is the identification of drugs that target myeloid cell immune regulatory receptors of which SIRP-alpha is a leading example.”
“We are dedicated to developing ground-breaking, first-in-class therapies that can transform the lives of patients and help win the fight against cancer.”
OSE Immunotherapeutics is engaged in the development of novel immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
With around 50,000 employees, Boehringer operates in the three business areas such as human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.